Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hermann Haller

Showing results (1-10 of 570) with videos related to

Pageof 57
Sort By:
Innere Medizin (Heidelberg, Germany)|February 22, 2023
[Nephrology: an update]Hermann Haller
Innere Medizin (Heidelberg, Germany)|November 8, 2022
[What is confirmed in treatment?]Hermann Haller
American Journal of Nephrology|September 16, 2021
The Embarrassment of Riches: Combining SGLT2 Inhibitors and Nonsteroidal Mineralocorticoid Antagonists for the Treatment of Diabetic Kidney DiseaseHermann Haller
Herz|September 12, 2022
Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trialHermann Haller
Biochemical Society Transactions|February 6, 2025
Current understanding of heparanase 2 regulation, a non-heparanaseYannic Becker, Hermann Haller
Herz|September 2, 2004
[Diabetic nephropathy - current concepts in early diagnosis and treatment of diabetic microvascular complications]Matthias Meier, Hermann Haller
Seminars in Hematology|July 17, 2007
Erythropoietin and treatment of non-anemic conditions--cardiovascular protectionDanilo Fliser, Hermann Haller
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
Fixed-dose lercanidipine/enalapril for hypertensionJan Menne, Hermann Haller
The New England Journal of Medicine|November 8, 2013
The role of the intrarenal resistive index in kidney transplantationJörg Radermacher, Hermann Haller
Nephron. Physiology|August 7, 2003
Participation of the mineralocorticoid receptor in cardiac and vascular remodelingAnette Fiebeler, Hermann Haller
Pageof 57

Showing results (1-10 of 570) with videos related to

Sort By:
Pageof 57
Innere Medizin (Heidelberg, Germany)|February 22, 2023
[Nephrology: an update]Hermann Haller
Innere Medizin (Heidelberg, Germany)|November 8, 2022
[What is confirmed in treatment?]Hermann Haller
American Journal of Nephrology|September 16, 2021
The Embarrassment of Riches: Combining SGLT2 Inhibitors and Nonsteroidal Mineralocorticoid Antagonists for the Treatment of Diabetic Kidney DiseaseHermann Haller
Herz|September 12, 2022
Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trialHermann Haller
Biochemical Society Transactions|February 6, 2025
Current understanding of heparanase 2 regulation, a non-heparanaseYannic Becker, Hermann Haller
Herz|September 2, 2004
[Diabetic nephropathy - current concepts in early diagnosis and treatment of diabetic microvascular complications]Matthias Meier, Hermann Haller
Seminars in Hematology|July 17, 2007
Erythropoietin and treatment of non-anemic conditions--cardiovascular protectionDanilo Fliser, Hermann Haller
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
Fixed-dose lercanidipine/enalapril for hypertensionJan Menne, Hermann Haller
The New England Journal of Medicine|November 8, 2013
The role of the intrarenal resistive index in kidney transplantationJörg Radermacher, Hermann Haller
Nephron. Physiology|August 7, 2003
Participation of the mineralocorticoid receptor in cardiac and vascular remodelingAnette Fiebeler, Hermann Haller
Pageof 57